EUVIMEDEUVIMED entdecken
Crossref

FDA approves drug to treat neurologic manifestations of Hunter syndrome

The Brown University Child & Adolescent Psychopharmacology Update · 2026-05 · 28 (5) · 8-8

DOI: 10.1002/cpu.31062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Brown University Child & Adolescent Psychopharmacology Update, online erschienen am 27.04.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The U.S. Food and Drug Administration approved Avlayah to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).

Zitieren

APA

(2026). FDA approves drug to treat neurologic manifestations of Hunter syndrome. The Brown University Child & Adolescent Psychopharmacology Update, 28(5), 8-8. https://doi.org/10.1002/cpu.31062

Vancouver

FDA approves drug to treat neurologic manifestations of Hunter syndrome. The Brown University Child & Adolescent Psychopharmacology Update. 2026;28(5):8-8. doi:10.1002/cpu.31062

BibTeX
@article{euvimed2026,
  title = {FDA approves drug to treat neurologic manifestations of Hunter syndrome},
  journal = {The Brown University Child & Adolescent Psychopharmacology Update},
  year = {2026},
  volume = {28},
  number = {5},
  pages = {8--8},
  doi = {10.1002/cpu.31062}
}
Kostenlos starten →